Sam Brusco, Associate Editor03.21.22
ZOLL Medical rolled out its ZOLL arrhythmia management system (AMS), a device that adds biometrix data to ECG information gathered by traditional mobile cardiac telemetry (MCT) devices.
A recent 583-patient MCT study (MAPS) compared traditional MCT reports with ZOLL AMS reports for the same cardiac events. Adding biometric data resulted in treatment plan changes for over 60% of patients, including adjustments to lifestyle, medications, and follow-up plans.
“The patient biometric data available from ZOLL AMS represents a leap forward in MCT technology,” Robert L. Salazar, MD, F.A.C.C., Texas Cardiology Associates of Houston, an investigator on the MAPS Trial, told the press. “ZOLL AMS data enhance the clinical picture by providing context to arrhythmic or symptomatic events. For example, a patient experiencing bradycardia while exercising would require a vastly different care plan than if they experience bradycardia while napping. With ZOLL AMS, we can get that level of clarity.”
ZOLLS AMS also offers timely event-based reports and comprehensive end-of-use reports including clinically relevant data like sleep, activity, respiratory rate, and patient status to asses broader health and guide treatment decisions.
“ZOLL AMS is the next generation of MCT with a feature set that significantly advances cardiac patient monitoring,” said Jason T. Whiting, president of ZOLL Cardiac Management Solutions. “ZOLL AMS now provides physicians with meaningful clinical value for all MCT patients, including those who do not experience an arrhythmia or symptoms. In the MAPS Trial, physicians reported that in patients who had no reported arrhythmias or symptoms, ZOLL AMS data helped them better understand the patient status compared to traditional ECG-only MCT data.”
A recent 583-patient MCT study (MAPS) compared traditional MCT reports with ZOLL AMS reports for the same cardiac events. Adding biometric data resulted in treatment plan changes for over 60% of patients, including adjustments to lifestyle, medications, and follow-up plans.
“The patient biometric data available from ZOLL AMS represents a leap forward in MCT technology,” Robert L. Salazar, MD, F.A.C.C., Texas Cardiology Associates of Houston, an investigator on the MAPS Trial, told the press. “ZOLL AMS data enhance the clinical picture by providing context to arrhythmic or symptomatic events. For example, a patient experiencing bradycardia while exercising would require a vastly different care plan than if they experience bradycardia while napping. With ZOLL AMS, we can get that level of clarity.”
ZOLLS AMS also offers timely event-based reports and comprehensive end-of-use reports including clinically relevant data like sleep, activity, respiratory rate, and patient status to asses broader health and guide treatment decisions.
“ZOLL AMS is the next generation of MCT with a feature set that significantly advances cardiac patient monitoring,” said Jason T. Whiting, president of ZOLL Cardiac Management Solutions. “ZOLL AMS now provides physicians with meaningful clinical value for all MCT patients, including those who do not experience an arrhythmia or symptoms. In the MAPS Trial, physicians reported that in patients who had no reported arrhythmias or symptoms, ZOLL AMS data helped them better understand the patient status compared to traditional ECG-only MCT data.”